[392例采用吡柔比星方案治疗的非霍奇金淋巴瘤患者的长期预后]

[Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens].

作者信息

Huang Hui-Qiang, Peng Yu-Long, Cai Qing-Qing, Lin X-Bin, Li Yu-Hong, Xia Zhong-Jun, Lin Tong-Yu, Sun Xiao-Fei, Zhang Li, Xu Guang-Chuan, He You-Jian, Jiang Wen-Qi, Guan Zhong-Zhen

机构信息

Department of Medical Oncology, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2005 Oct;26(10):577-80.

PMID:16532963

Abstract

OBJECTIVE

To analyse the effectiveness and toxicity of combined chemotherapy regimen containing pirarubicin (THP) in the treatment of non-Hodgkin's lymphoma (NHL).

METHODS

Three hundred and ninety two patients with NHL were treated by THP containing regimen with or without involved field radiotherapy. The clinical characteristics, response, toxicity and long-term survival rates were analysed.

RESULTS

The median age of the patients was 47 (5 - 87) years and 26.0% aged more than 60 years. 61.0% of the patients were males and 39.0% females. B-cell and T/NK cell NHL accounted for 68.4% and 23.2% respectively with 56.9% of diffuse large B cell lymphoma and 12.5% of peripheral T cell lymphoma. 92.6% of the patients were ECOG < 1, 63.2% in stage I + II, 84.7% with IPI score 0 - 2 and 25% with B symptoms, 93.9% (368/392) of the patients received CTOP (containing THP) regimen chemotherapy and among them 28.5% (112/392) plus involved field radiotherapy. Altogether 1598 courses were administered on 368 patients. The overall response rate was 88.5% (341/385) with a complete remission (CR) rate of 63.6%, major toxicity was myelosuppression with 12.8%, 1.0% and 1.5% of grade III - IV neutropenia, thrombocytopenia and anemia, respectively. G-CSF support was given for 553 courses (34.6%). Alopecia account for 19.8%. The incidence of mild cardiotoxicity was 5.8%. Treatment-related mortality was 1.6% (6/368). Median follow-up was 24 months. The 1, 3 and 5 year actuarial survival rates were 86.4% , 66.5% and 59.2%, respectively. Median survival time has not been achieved.

CONCLUSION

The efficacy of THP based regimen CTOP for the treatment of aggressive NHL is promising. Further clinical trial is warranted.

摘要

目的

分析含吡柔比星（THP）的联合化疗方案治疗非霍奇金淋巴瘤（NHL）的有效性和毒性。

方法

392例NHL患者接受含THP方案治疗，部分患者联合受累野放疗。分析患者的临床特征、疗效、毒性及长期生存率。

结果

患者中位年龄47（5 - 87）岁，26.0%年龄超过60岁。男性占61.0%，女性占39.0%。B细胞型和T/NK细胞型NHL分别占68.4%和23.2%，其中弥漫大B细胞淋巴瘤占56.9%，外周T细胞淋巴瘤占12.5%。92.6%的患者ECOG < 1，63.2%为Ⅰ + Ⅱ期，84.7%的国际预后指数（IPI）评分为0 - 2，25%有B症状。93.9%（368/392）的患者接受CTOP（含THP）方案化疗，其中28.5%（112/392）联合受累野放疗。共对368例患者进行了1598个疗程的治疗。总缓解率为88.5%（341/385），完全缓解（CR）率为63.6%，主要毒性为骨髓抑制，Ⅲ - Ⅳ级中性粒细胞减少、血小板减少和贫血的发生率分别为12.8%、1.0%和1.5%。553个疗程（34.6%）给予粒细胞集落刺激因子（G-CSF）支持。脱发发生率为19.8%。轻度心脏毒性发生率为5.8%。治疗相关死亡率为1.6%（6/368）。中位随访时间为24个月。1年、3年和5年的精算生存率分别为86.4%、66.5%和59.2%。中位生存时间尚未达到。